BioPharma Credit PLC (LON: BPCR)
London
· Delayed Price · Currency is GBP · Price in USD0.852
+0.002 (0.24%)
Dec 23, 2024, 4:35 PM BST
BioPharma Credit Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Other Revenue | 136.37 | 135.74 | 218.17 | 103.88 | 110.02 | 150.91 | Upgrade
|
| Revenue | 136.37 | 135.74 | 218.17 | 103.88 | 110.02 | 150.91 | Upgrade
|
| Revenue Growth (YoY) | -38.22% | -37.78% | 110.02% | -5.58% | -27.09% | 55.06% | Upgrade
|
| Gross Profit | 136.37 | 135.74 | 218.17 | 103.88 | 110.02 | 150.91 | Upgrade
|
| Selling, General & Admin | 26.91 | 27.28 | 35.79 | 18.95 | 20.87 | 28.57 | Upgrade
|
| Other Operating Expenses | 0.09 | 0 | 0.04 | -0.05 | - | - | Upgrade
|
| Operating Expenses | 27 | 27.28 | 35.83 | 18.9 | 20.87 | 28.57 | Upgrade
|
| Operating Income | 109.37 | 108.46 | 182.34 | 84.98 | 89.15 | 122.34 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.01 | -0.01 | -0.03 | -0.02 | -0.01 | -0.01 | Upgrade
|
| Pretax Income | 109.36 | 108.45 | 182.31 | 84.96 | 89.14 | 122.33 | Upgrade
|
| Net Income | 109.36 | 108.45 | 182.31 | 84.96 | 89.14 | 122.33 | Upgrade
|
| Net Income to Common | 109.36 | 108.45 | 182.31 | 84.96 | 89.14 | 122.33 | Upgrade
|
| Net Income Growth | -40.91% | -40.51% | 114.59% | -4.69% | -27.13% | 74.39% | Upgrade
|
| Shares Outstanding (Basic) | 1,274 | 1,309 | 1,364 | 1,374 | 1,374 | 1,374 | Upgrade
|
| Shares Outstanding (Diluted) | 1,274 | 1,309 | 1,364 | 1,374 | 1,374 | 1,374 | Upgrade
|
| Shares Change (YoY) | -4.55% | -4.00% | -0.72% | -0.00% | -0.00% | 38.90% | Upgrade
|
| EPS (Basic) | 0.09 | 0.08 | 0.13 | 0.06 | 0.06 | 0.09 | Upgrade
|
| EPS (Diluted) | 0.09 | 0.08 | 0.13 | 0.06 | 0.06 | 0.09 | Upgrade
|
| EPS Growth | -38.09% | -38.03% | 116.14% | -4.68% | -27.13% | 25.55% | Upgrade
|
| Free Cash Flow | 140.42 | 123.18 | 184.28 | 96.44 | 58.07 | 131.52 | Upgrade
|
| Free Cash Flow Per Share | 0.11 | 0.09 | 0.14 | 0.07 | 0.04 | 0.10 | Upgrade
|
| Dividend Per Share | 0.070 | 0.070 | 0.070 | 0.070 | 0.070 | 0.070 | Upgrade
|
| Dividend Growth | 0% | 0% | 0% | 0% | 0% | 6.22% | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | 80.20% | 79.90% | 83.58% | 81.80% | 81.03% | 81.07% | Upgrade
|
| Profit Margin | 80.20% | 79.90% | 83.56% | 81.79% | 81.02% | 81.06% | Upgrade
|
| Free Cash Flow Margin | 102.97% | 90.75% | 84.47% | 92.83% | 52.78% | 87.15% | Upgrade
|
| EBIT | 109.37 | 108.46 | 182.34 | 84.98 | 89.15 | 122.34 | Upgrade
|
| EBIT Margin | 80.20% | 79.90% | 83.58% | 81.80% | 81.03% | 81.07% | Upgrade
|
| Revenue as Reported | 136.36 | 135.73 | 218.14 | 103.86 | 110.01 | 150.89 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.